Stockreport

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven Ltd. Common Shares  (BHVN) 
Last biohaven ltd. common shares earnings: 2/25 04:45 pm Check Earnings Report
US:NYSE Investor Relations: investors.biohavenpharma.com